121 related articles for article (PubMed ID: 15259024)
41. Effect of antibody to CD134 on perforin-mediated cytolysis in human peripheral blood mononuclear cells.
Li M; Zhang Y
Hybridoma (Larchmt); 2006 Jun; 25(3):145-53. PubMed ID: 16796461
[TBL] [Abstract][Full Text] [Related]
42. Expression of CD134 and CD134 ligand in lesional and nonlesional psoriatic skin.
Matsumura Y; Hori T; Nishigori C; Shirogane K; Toda KI; Uchiyama T; Tanaka Y; Miyachi Y
Arch Dermatol Res; 2003 Mar; 294(12):563-6. PubMed ID: 12624783
[No Abstract] [Full Text] [Related]
43. Strong expression of CD134 (OX40), a member of the TNF receptor family, in a T helper 2-type cytokine environment.
Roos A; Schilder-Tol EJ; Weening JJ; Aten J
J Leukoc Biol; 1998 Oct; 64(4):503-10. PubMed ID: 9766631
[TBL] [Abstract][Full Text] [Related]
44. Regulation of Bcl-2 proteins during anoikis and amorphosis.
Martin SS; Vuori K
Biochim Biophys Acta; 2004 Jul; 1692(2-3):145-57. PubMed ID: 15246684
[TBL] [Abstract][Full Text] [Related]
45. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system.
Barlow PG; Li Y; Wilkinson TS; Bowdish DM; Lau YE; Cosseau C; Haslett C; Simpson AJ; Hancock RE; Davidson DJ
J Leukoc Biol; 2006 Sep; 80(3):509-20. PubMed ID: 16793910
[TBL] [Abstract][Full Text] [Related]
46. Granzyme B-mediated apoptosis--the elephant and the blind men?
Froelich CJ; Metkar SS; Raja SM
Cell Death Differ; 2004 Apr; 11(4):369-71. PubMed ID: 14726962
[No Abstract] [Full Text] [Related]
47. Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: a general mechanism to accumulate effector cells in inflammation.
Dibbert B; Weber M; Nikolaizik WH; Vogt P; Schöni MH; Blaser K; Simon HU
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13330-5. PubMed ID: 10557320
[TBL] [Abstract][Full Text] [Related]
48. CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis.
Boot EP; Koning GA; Storm G; Wagenaar-Hilbers JP; van Eden W; Everse LA; Wauben MH
Arthritis Res Ther; 2005; 7(3):R604-15. PubMed ID: 15899047
[TBL] [Abstract][Full Text] [Related]
49. Localization of linear cytotoxic and pro-apoptotic epitopes in RTX toxin ApxIII of Actinobacillus pleuropneumoniae.
Seah JN; Kwang J
Vaccine; 2004 Mar; 22(11-12):1494-7. PubMed ID: 15063574
[TBL] [Abstract][Full Text] [Related]
50. Molecular control of neutrophil apoptosis.
Akgul C; Moulding DA; Edwards SW
FEBS Lett; 2001 Jan; 487(3):318-22. PubMed ID: 11163351
[TBL] [Abstract][Full Text] [Related]
51. OX40 signaling renders adult T-cell leukemia cells resistant to Fas-induced apoptosis.
Kunitomi A; Hori T; Maeda M; Uchiyama T
Int J Hematol; 2002 Oct; 76(3):260-6. PubMed ID: 12416737
[TBL] [Abstract][Full Text] [Related]
52. Apoptosis and Bax, Bcl-2, Mcl-1 expression in neutrophils of Crohn's disease patients.
Catarzi S; Marcucci T; Papucci L; Favilli F; Donnini M; Tonelli F; Vincenzini MT; Iantomasi T
Inflamm Bowel Dis; 2008 Jun; 14(6):819-25. PubMed ID: 18266233
[TBL] [Abstract][Full Text] [Related]
53. Apoptotic neutrophils in the circulation of patients with glycogen storage disease type 1b (GSD1b).
Kuijpers TW; Maianski NA; Tool AT; Smit GP; Rake JP; Roos D; Visser G
Blood; 2003 Jun; 101(12):5021-4. PubMed ID: 12576310
[TBL] [Abstract][Full Text] [Related]
54. Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay.
Taylor L; Schwarz H
J Immunol Methods; 2001 Sep; 255(1-2):67-72. PubMed ID: 11470287
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms regulating neutrophil survival and cell death.
Gabelloni ML; Trevani AS; Sabatté J; Geffner J
Semin Immunopathol; 2013 Jul; 35(4):423-37. PubMed ID: 23370701
[TBL] [Abstract][Full Text] [Related]
56. Breaking immunological tolerance through OX40 (CD134).
Bansal-Pakala P; Croft M
ScientificWorldJournal; 2001 Nov; 1():633-5. PubMed ID: 12805765
[TBL] [Abstract][Full Text] [Related]
57. Apoptosis in transfusion medicine: of death and dying--is that all there is?
Snyder EL; Kuter DJ
Transfusion; 2000 Feb; 40(2):135-8. PubMed ID: 10685996
[No Abstract] [Full Text] [Related]
58. Could OX40 agonist antibody promote activation of the anti-tumor immune response in gastric cancer?
Martins MR; Santos RLD; Jatahy KDN; Matta MCD; Batista TP; Júnior JIC; Begnami MDFS; Torres LC
J Surg Oncol; 2018 Apr; 117(5):840-844. PubMed ID: 29529339
[TBL] [Abstract][Full Text] [Related]
59. OX40, OX40L and Autoimmunity: a Comprehensive Review.
Webb GJ; Hirschfield GM; Lane PJ
Clin Rev Allergy Immunol; 2016 Jun; 50(3):312-32. PubMed ID: 26215166
[TBL] [Abstract][Full Text] [Related]
60. Science gone translational: the OX40 agonist story.
Weinberg AD; Morris NP; Kovacsovics-Bankowski M; Urba WJ; Curti BD
Immunol Rev; 2011 Nov; 244(1):218-31. PubMed ID: 22017441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
